Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced the appointment of pharmaceutical industry veteran Mark Kreston as its Chief Commercial Officer. Kreston has more than 30 years of experience with global pharmaceutical companies spanning all phases of commercialization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005127/en/
Mark Kreston, Chief Commercial Officer, Knopp Biosciences (Photo: Business Wire)
In his new role, Kreston will establish and execute global commercialization strategies and plans across the Knopp enterprise, with a particular focus on the Company’s lead program, dexpramipexole, an investigational drug candidate poised to enter Phase 3 trials in hypereosinophilic syndrome and Phase 2 trials in eosinophilic asthma. He will also be responsible for leading Knopp’s corporate strategy and business development activities, and will play a key role in the Company’s capital strategy.
“We are thrilled to welcome Mark to the Knopp team at this pivotal moment in our corporate development,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “His track record of launching major pharmaceutical products, including several blockbuster brands in the immunology sector, and his success in marketing oral products for conditions dominated by established biologics, will be invaluable as we advance dexpramipexole as a potential new treatment for eosinophil-associated diseases.”
Prior to joining Knopp, Kreston was corporate VP of Global Marketing, Inflammation & Immunology at Celgene, where he led the launch of Otezla for psoriasis. Before that, he served as worldwide VP of Global Marketing, Immunology at Johnson & Johnson, where he helped engineer global expansion of the company’s immunology business for Remicade and Stelara. Earlier, at Bristol-Myers Squibb, he was worldwide VP of Global Marketing, Immunology, responsible for launching Orencia for rheumatoid arthritis, and served as President of Consumer Medicines. Early in his career, he was product manager for Tylenol and Pepcid at McNeil Consumer Healthcare. Kreston holds a bachelor’s degree from the University of Pennsylvania and an MBA from the Cornell Johnson Graduate School of Management.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com.
Forward Looking Statement
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
Tel: +1 203 682 8251
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck26.3.2019 12:17:00 EET | Tiedote
Enamine Ltd. a provider of integrated drug discovery services empowered by the world’s largest collections of building blocks and screening compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical company involved in the research of new drugs for the treatment of disorders in the central nervous system, today announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs. A large diverse library of 100,000 new screening compounds for hit finding activities on numerous therapeutic targets. Enamine’s make-on-demand REAL compounds (Nature, 2019, Vol. 566, p. 224–229) for efficient access to billions of novel chemical compounds. An increased dedicated team of Enamine FTE chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170
Acuris Risk Intelligence launches Acuris Cybercheck26.3.2019 12:00:00 EET | Tiedote
Acuris Risk Intelligence, a trusted and independent provider of data intelligence for anti-money laundering, anti-corruption and cyber security professionals, today announces the launch of Acuris Cybercheck, a database that allows businesses and individuals to identify whether or not their information has been compromised by criminals. Acuris Cybercheck provides the largest proprietary database of compromised personal ID data. Complied since 2008, the database includes information traded on criminal websites globally such as identity, personal and financial data. It also allows users to search via APIs against specific records or to continuously monitor data. The database is a one-stop shop for monitoring compromised data, allowing users to, among other things, proactively monitor personal data and receive alerts, mitigate identified risks, improve GDPR compliance, provide evidence of potential data breach and assess data compromise in M&A and corporate transactions. The system uses sk
GlobalLogic Appoints Veteran CEO Björn Ivroth as Board Advisor26.3.2019 11:00:00 EET | Tiedote
GlobalLogic Inc., a leader in digital product engineering, today announced that, effective immediately, Björn Ivroth joins the company as an advisor to its Board of Directors. Mr. Ivroth recently served as the CEO of EVRY, a leading Nordic IT services and software provider. In this role, he will work alongside the Board, the CEO, and fellow accomplished leaders contributing to the development and execution of growth strategies driving GlobalLogic’s European business. “We are thrilled to have someone of Björn’s caliber as part of our advisory team,” said Shashank Samant, CEO, GlobalLogic. “His experience as an operating leader, and deep knowledge of the European market are tremendous assets to GlobalLogic, and we are looking forward to leveraging his expertise as we continue to expand our European footprint.” Mr. Ivroth started his career as a Management Consultant at McKinsey & Company. Other early experiences include leadership roles focused on IT Services at Accenture and IBM. His ca
European MSPs Could Lose SMB Clients Over Cybersecurity: Vanson Bourne Report26.3.2019 11:00:00 EET | Tiedote
Cybersecurity demands of small- and medium-sized businesses (SMBs) have become both a major risk and revenue opportunity to managed service providers (MSPs). This is according to research conducted by Vanson Bourne and commissioned by Continuum ®, the proactive platform that integrates intelligent software with expert services for MSPs to scale dynamically and protect their clients. Underserved and Unprepared: The State of SMB Cyber Security in 2019, released today, draws on data collected in 2019 from 850 SMBs across the United States, United Kingdom, France, Germany and Belgium. In addition to the risks for MSPs, the report also highlights the significant revenue opportunity for providers that deliver the cybersecurity services and solutions SMBs need to protect their businesses. Vanson Bourne’s research in the four European countries found that MSPs are at risk of losing their SMB clients over cybersecurity concerns. More than nine in ten (93 percent) SMBs would consider hiring a ne
Evaluate Ltd. Appoints Deborah Kobewka as Chief Executive Officer26.3.2019 11:00:00 EET | Tiedote
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Deborah Kobewka as Chief Executive Officer, effective immediately. Deborah succeeds Alex Karle, who joined Evaluate in 2012 as Chief Operating Officer before assuming the role of CEO in 2014. Deborah brings to Evaluate over 30 years of expertise in the global pharmaceutical, healthcare and information sectors. With her successful track record of driving commercial expansion, she is well positioned to accelerate the company’s current growth trajectory. Deborah joins Evaluate from the Department for International Trade in the UK government where she served as Managing Director of Healthcare UK, Lifesciences and Bio-economy. Prior to that, she held senior corporate and operational roles at both private and government organisations in the UK, Europe and Asia, including 24 years at IMS Health (now IQVIA). “Evaluate has an impressive history of pioneering solutions
Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EET | Tiedote
Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme